Literature DB >> 19575825

Health technology assessment development in China.

Yingyao Chen1, David Banta, Zhiliu Tang.   

Abstract

OBJECTIVES: This study is to review health technology assessment (HTA) development in China during the past two decades, and to facilitate further development of HTA and its integration into policy making.
METHODS: The study depends very much on the extensive experiences of the authors in involvement of HTA in China. In addition, literature review and Web site searching have been used to trace the process of growth of HTA in China.
RESULTS: With its rapid economic development, the Chinese health system has had many achievements in the past 30 years. However, there are some weaknesses that have developed during this period. HTA is traced back to the early 1990s in China. First, HTA knowledge transfer and establishment of HTA units were effective ways to develop HTA in China. By the end of 1990s, the policy makers of the Ministry of Health (MoH) made efforts to merge HTA with policy making to improve the quality and efficiency of health care. The main government authorities related to health technology are the State Food and Drug Administration, the Ministry of Labor and Social Security, and the MoH. Their involvements in HTA are varied.
CONCLUSION: A technology licensure mechanism based on HTA, including technology permission for use, institution licensure, and workforce licensure, is being gradually carried out by the MoH in China. Moreover, HTA can play an important role in technology market entry, insurance benefit coverage, formulary, clinical pathway, reimbursement, and so on. There is a great opportunity for HTA to be an important part of health reform, especially to help policy makers within the health sector to make difficult decisions.

Mesh:

Year:  2009        PMID: 19575825     DOI: 10.1017/S0266462309090643

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  5 in total

1.  Mapping between HAQ-DI and EQ-5D-5L in a Chinese patient population.

Authors:  Thomas Patton; Hao Hu; Luan Luan; Keqin Yang; Shu-Chuen Li
Journal:  Qual Life Res       Date:  2018-07-04       Impact factor: 4.147

2.  Health technology assessment in Iran: challenges and views.

Authors:  Alireza Olyaeemanesh; Shila Doaee; Mohammadreza Mobinizadeh; Mina Nedjati; Parisa Aboee; Seyed Hassan Emami-Razavi
Journal:  Med J Islam Repub Iran       Date:  2014-12-29

3.  Determinants of knowledge translation from health technology assessment to policy-making in China: From the perspective of researchers.

Authors:  Wenbin Liu; Lizheng Shi; Raymond W Pong; Hengjin Dong; Yiwei Mao; Meng Tang; Yingyao Chen
Journal:  PLoS One       Date:  2018-01-04       Impact factor: 3.240

4.  Strengthening health technology assessment systems in the global south: a comparative analysis of the HTA journeys of China, India and South Africa.

Authors:  Kim MacQuilkan; Peter Baker; Laura Downey; Francis Ruiz; Kalipso Chalkidou; Shankar Prinja; Kun Zhao; Thomas Wilkinson; Amanda Glassman; Karen Hofman
Journal:  Glob Health Action       Date:  2018       Impact factor: 2.640

5.  Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?

Authors:  Cong Huang; Carolina Oi Lam Ung; Haishaerjiang Wushouer; Lin Bai; Tao Huang; Xinyi Li; Xiaodong Guan; Luwen Shi
Journal:  Health Res Policy Syst       Date:  2022-01-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.